Case 3:18-cv-00347-CAB-MDD Document 300-15 Filed 01/08/21 PageID.27088 Page 1 of 8
`
`EXHIBIT 14
`
`EXHIBIT 14 - Page 161
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-15 Filed 01/08/21 PageID.27089 Page 2 of 8
`
`
`
`Wilson Sonsini Goodrich & Rosati P.C.
`PAUL D. TRIPODI II (SBN 162380)
`ptripodi@wsgr.com
`GRACE J. PAK (SBN 277705)
`gpak@wsgr.com
`633 West Fifth Street, Suite 1550
`Los Angeles, CA 90071
`Telephone: 323-210-2900
`Fax: 866-974-7329
`
`WENDY L. DEVINE (SBN 246337)
`wdevine@wsgr.com
`One Market Plaza
`Spear Tower, Suite 3300
`San Francisco, California 94105-1126
`Telephone: 415-947-2000
`Fax: 415-947-2099
`
`NATALIE J. MORGAN (SBN 211143)
`nmorgan@wsgr.com
`CHRISTINA DASHE (SBN 292360)
`cdashe@wsgr.com
`12235 El Camino Real
`San Diego, CA 92130
`Telephone: 858-350-2300
`Fax: 858-350-2399
`
`SARA L. TOLBERT (SBN 300945)
`stolbert@wsgr.com
`650 Page Mill Road
`Palo Alto, CA 94304
`Telephone: 650-593-9300
`Fax: 650-493-6811
`
`Attorneys for Plaintiff NuVasive, Inc.
`
`UNITED STATES DISTRICT COURT
`
`SOUTHERN DISTRICT OF CALIFORNIA
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`Plaintiff,
`
`
`
`
`
`v.
`
`SAN DIEGO DIVISION
`NUVASIVE, INC., a Delaware
`)
`CASE NO. 18-cv-00347-CAB-MDD
`corporation,
`)
`
`)
`
`)
`PLAINTIFF NUVASIVE, INC.’S
`)
`RESPONSES TO DEFENDANTS’
`)
`FIRST SET OF
`)
`INTERROGATORIES (NOS. 1-12)
`)
`)
`)
`)
`)
`)
`)
`
`ALPHATEC HOLDINGS, INC., a
`Delaware corporation and ALPHATEC
`SPINE, INC., a California corporation,,
`
`
`Defendants.
`
`NUVASIVE’S RESPONSES TO DEFENDANTS’
`FIRST SET OF INTERROGATORIES (NOS. 1-12)
`
`
`
`
`3:18-CV-00347-CAB-MDD
`
`EXHIBIT 14 - Page 162
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-15 Filed 01/08/21 PageID.27090 Page 3 of 8
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`Pursuant to Rules 26 and 34 of the Federal Rules of Civil Procedure, Plaintiff
`
`NuVasive, Inc. (“NuVasive”), by and through its undersigned counsel, hereby
`
`responds to Defendants Alphatec Holdings, Inc. and Alphatec Spine, Inc.’s
`
`(collectively “Alphatec” or “Defendants”) First Set of Interrogatories (Nos. 1-12) as
`
`follows:
`
`GENERAL OBJECTIONS
`
`In addition to any specifically stated objections, NuVasive’s responses
`
`herein are subject to and incorporate the following general objections:
`
`1.
`
`NuVasive asserts each of the following General Objections and
`
`expressly incorporates them into each response set forth below. By providing a
`
`response to any interrogatory, NuVasive does not waive or otherwise limit these
`
`General Objections. Furthermore, reference to any of these General Objections in
`
`any specific response shall not waive or otherwise limit the applicability of all of
`
`these General Objections to each and every response.
`
`2.
`
`NuVasive objects to all definitions, instructions, and interrogatories to
`
`the extent that they are unduly burdensome and oppressive, overly broad, vague,
`
`ambiguous and/or to the extent it is inconsistent with and/or seeks to impose upon
`
`NuVasive obligations beyond those required by the Federal Rules of Civil
`
`Procedure, the Local Rules of the United States District Court for the Southern
`
`District of California or any Court Order in this matter, including this Court’s
`
`Scheduling Order. In responding to these interrogatories, NuVasive will only
`
`comply with the obligations imposed on it by the Federal Rules of Civil Procedure,
`
`the Local Rules of the United States District Court for the Southern District of
`
`California, any applicable orders of this Court, and any stipulation or agreement
`
`between the parties.
`
`3.
`
`NuVasive objects to all definitions, instructions, and interrogatories to
`
`the extent that they seek the disclosure of information that is not relevant to any
`
`party’s claim or defense and proportional to the needs of the case.
`
`NUVASIVE’S RESPONSES TO DEFENDANTS’
`FIRST SET OF INTERRGATORIES (NOS. 1-12)
`
`
`-1-
`
`3:18-CV-00347-CAB-MDD
`
`EXHIBIT 14 - Page 163
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-15 Filed 01/08/21 PageID.27091 Page 4 of 8
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`
`
`In addition, the following are publicly available documents from which the
`
`information requested can be ascertained: Public records of the documents filed in
`
`the inter partes review proceedings for U.S. Patent Nos. 8,192,356; 8,000,782;
`
`8,016,767; 7,582,058; 8,005,535; 8,361,156; and 8,187,334; and public records of
`
`the documents filed in the reexamination proceedings for U.S. Patent Nos.
`
`7,819,801; 7,570,236; 7,691,057; 7,582,058; and 7,207,949.
`
`Discovery is ongoing and NuVasive reserves its right to amend or
`
`supplement its response to this interrogatory.
`
`INTERROGATORY NO. 3:
`
`For each asserted claim of the patents-in-suit, describe in detail the facts and
`
`circumstances relating to the first written description, offer for sale, sale, public
`
`disclosure, public use, or disclosure to any person other than a named inventor of
`
`the claimed invention, including, without limitation, the identities of the persons
`
`involved in each such event, the identities of the persons most knowledgeable
`
`regarding each such event, the date on which each such event occurred, and the
`
`identification of each document that reflects or relates to such facts and
`
`circumstances.
`
`RESPONSE TO INTERROGATORY NO. 3:
`
`NuVasive incorporates by reference each of the General Objections.
`
`NuVasive objects to this interrogatory on the grounds that it contains at least three
`
`discrete subparts, is compound, and constitutes at least three interrogatories.
`
`NuVasive objects to this interrogatory as vague and ambiguous with respect to the
`
`term “the circumstances.” NuVasive objects to this interrogatory on the grounds
`
`and to the extent it is overly broad, unduly burdensome, not proportional to the
`
`needs of the case, and not relevant to any claim or defense in this case.
`
`Specifically, NuVasive objects to the interrogatory to the extent it calls for
`
`NuVasive to “describe in detail” the circumstances relating to the first descriptions,
`
`NUVASIVE’S RESPONSES TO DEFENDANTS’
`FIRST SET OF INTERROGATORIES (NOS. 1-12)
`
`
`
`16
`
`3:18-CV-00347-CAB-MDD
`
`EXHIBIT 14 - Page 164
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-15 Filed 01/08/21 PageID.27092 Page 5 of 8
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`
`
`disclosures and sales of the claimed inventions. NuVasive objects to this
`
`interrogatory to the extent it seeks “Privileged Information.” NuVasive objects to
`
`this interrogatory to the extent it calls for legal conclusions. NuVasive objects to
`
`this interrogatory to the extent it attempts the shift the burden of proof regarding
`
`invalidity to NuVasive. NuVasive objects to this interrogatory to the extent it
`
`seeks information no longer in NuVasive’s possession, custody, or control.
`
`Subject to and without waiving the foregoing objections, NuVasive responds
`
`as follows: the first written description for each of the patents-in-suit is at least as
`
`early as the earliest priority date of the respective patent-in-suit based on the
`
`earliest filed parent patent application.
`
`Additionally, Alphatec has admitted that NuVasive’s “eXtreme Lateral
`
`Interbody Fusion” product (or “XLIF”), which includes the MaXcess access
`
`system and CoRoent XL implants, embodies the asserted claims of the patents-in-
`
`suit. Doc. No. 48 at 16. Based on information available to NuVasive at this time,
`
`NuVasive states that it launched aspects of XLIF in October 2003 at the North
`
`American Spine Society (NASS) Annual Meeting, including its MaXcess access
`
`system, and specifically MaXcess I. Persons involved in this this launch include
`
`Pat Miles, Eric Finley, and Scott Martinelli. In addition, MaXcess III launched on
`
`September 12, 2006, and MaXcess III Solid launched on November 13, 2008.
`
`In October 2004, at NASS, NuVasive launched the CoRoent XL implant as
`
`part of XLIF. The persons involved in the launch of CoRoent XL are Matthew
`
`Curran, Matthew Copp, Scott Martinelli, Patrick Miles, and David Ivanko.
`
`In addition, pursuant to Local Patent Rule 3.2(b) and Fed. R. Civ. P. 33(d),
`
`NuVasive further states that it will produce and has produced non-privileged
`
`documents from which the information requested can be ascertained, including
`
`documents bearing the following Bates numbers:
`
`NUVA_ATEC0000001 – NUVA_ATEC0000290;
`
`NUVASIVE’S RESPONSES TO DEFENDANTS’
`FIRST SET OF INTERROGATORIES (NOS. 1-12)
`
`
`
`17
`
`3:18-CV-00347-CAB-MDD
`
`EXHIBIT 14 - Page 165
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-15 Filed 01/08/21 PageID.27093 Page 6 of 8
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`
`
`
`NUVA_ATEC0000544 – NUVA_ATEC0014446;
`
`NUVA_ATEC0014504 – NUVA_ATEC0015487;
`
`NUVA_ATEC0016164 – NUVA_ATEC0016948;
`
`NUVA_ATEC0016949 – NUVA_ATEC0039458;
`
`NUVA_ATEC0039459 – NUVA_ATEC0040421.
`
`Discovery is ongoing and NuVasive reserves its right to amend or
`
`supplement its response to this interrogatory.
`
`INTERROGATORY NO. 4:
`
`
`
`For each of the patents-in-suit, provide all facts and
`
`identify all
`
`corroborating documents regarding the ownership of any right, title, or interest in
`
`or to each patent, including identifying the entity that currently owns the right,
`
`title, or interest; a full explanation of the chain of title to any and all rights, title, or
`
`interests in or to each patent; and the circumstances regarding each entity’s
`
`assignment/acquisition of any right, title, or interest in each of the patents-in-suit
`
`(including, without limitation, the reasons for assignment; dates of acquisition;
`
`valuation of the patents-in-suit; and identification of all individuals knowledgeable
`
`regarding the assignment and/or involved in a negotiation of the assignment, the
`
`persons most knowledgeable regarding the assignment and/or negotiation of the
`
`assignment, and all documents and communications related to such assignment
`
`and/or negotiation of the assignment).
`
`RESPONSE TO INTERROGATORY NO. 4:
`
`NuVasive incorporates by reference each of the General Objections.
`
`NuVasive objects to this interrogatory on the grounds that it contains at least two
`
`discrete subparts, is compound, and constitutes at least two interrogatories. For
`
`example, information regarding any “valuation(s) of the patents-in-suit” is
`
`completely unrelated to information regarding “ownership of any right title, or
`
`interest” in the patents-in-suit. NuVasive objects to this interrogatory as vague and
`
`NUVASIVE’S RESPONSES TO DEFENDANTS’
`FIRST SET OF INTERROGATORIES (NOS. 1-12)
`
`
`
`18
`
`3:18-CV-00347-CAB-MDD
`
`EXHIBIT 14 - Page 166
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-15 Filed 01/08/21 PageID.27094 Page 7 of 8
`
`Dated: September 4, 2018
`
`WILSON SONSINI GOODRICH & ROSATI PC
`Professional Corporation
`
`By: /s/ Grace J. Pak
`Paul D. Tripodi II
`State Bar No. 162380
`ptripodi@wsgr.com
`Grace J. Pak
`State Bar No. SBN 277705
`gpak@wsgr.com
`633 West Fifth Street, Suite 1550
`Los Angeles, CA 90071
`Telephone: 323-210-2900
`Fax: 866-974-7329
`
`Natalie J. Morgan
`State Bar No. 211143
`nmorgan@wsgr.com
`Christina Dashe
`State Bar No. 292360
`cdashe@wsgr.com
`12235 El Camino Real
`San Diego, CA 92130
`Telephone: 858-350-2300
`Fax: 858-350-2399
`
`Wendy L. Devine
`State Bar No. 246337
`wdevine@wsgr.com
`One Market Plaza
`Spear Tower, Suite 3300
`San Francisco, California 94105-1126
`Telephone: 415-947-2000
`Fax: 415-947-2099
`
`Sara L. Tolbert
`State Bar No. 300945
`stolbert@wsgr.com
`650 Page Mill Road
`Palo Alto, CA 94304
`Telephone: 650-593-9300
`Fax: 650-493-6811
`
`Attorneys for Plaintiff NuVasive, Inc.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`NUVASIVE’S RESPONSES TO DEFENDANTS’
`FIRST SET OF INTERROGATORIES (NOS. 1-12)
`
`
`40
`
`3:18-CV-00347-CAB-MDD
`
`EXHIBIT 14 - Page 167
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-15 Filed 01/08/21 PageID.27095 Page 8 of 8
`
`
`
`
`CERTIFICATE OF SERVICE
`
`I, Grace J. Pak, am employed by Wilson Sonsini Goodrich & Rosati, P.C. I
`
`am over the age of 18 and not a party to the within action. My business address is
`
`633 West Fifth Street, Suite 1550, Los Angeles, CA 90071. I certify that a copy of
`
`the foregoing PLAINTIFF NUVASIVE, INC.’S RESPONSES TO
`
`DEFENDANTS’ FIRST SET OF INTERRGATORIES (NOS. 1-12) was
`
`served via messenger service on the following:
`
`Stephen R. Smerek
`Nimalka R. Wickramasekera
`WINSTON & STRAWN LLP
`333 S. Grand Avenue
`38th Floor
`Los Angeles, CA 90071-1543
`
`I declare under penalty of perjury under the Laws of the United States of
`
`America that the above is true and correct. Executed this 4th day of September,
`
`2018, at Los Angeles, California.
`
`
`
`By: /s/ Grace J. Pak
`Grace J. Pak
`
`
`
`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`CERTIFICATE OF SERVICE
`
`
`-1-
`
`3:18-CV-00347-CAB-MDD
`
`EXHIBIT 14 - Page 168
`
`